Faegre Drinker Biddle & Reath LLP, a Delaware limited liability partnership | This website contains attorney advertising.

FDA-Regulated Products

Overview

Like the agency itself, we have dedicated, interdisciplinary practices focusing on each segment of the Food and Drug Administration (FDA) and the Federal Food, Drug and Cosmetic Act (FDCA). We partner with stakeholders in the food, pharmaceutical, health and life sciences, and other affected industries to navigate FDA regulations and agency interactions. Companies, patient organizations, and other stakeholders rely on us to provide experienced advice to help them meet regulatory expectations and navigate the FDA when they’re working with new drugs, biologics, and medical devices and related biotechnology or innovative food products and cosmetics.

Drugs and Medical Devices

As a drug and medical device innovator, patient organization, or other stakeholder in the drug or device approval process, your success relies on your ability to comply with a complex framework of regulations related to research and development, marketing authorization, and post-marketing compliance. We support you throughout the life cycle of a medical product — from the early research stages to the clinic, to Agency submission and approval, and on to post-marketing commitments and ongoing safety monitoring. 

Our experienced team members have worked on issues before the FDA’s Center for Drug Evaluation and Research including drug and biologics policy matters before the Office of Pharmaceutical Quality and compliance matters (including 483 responses and warning letters) before the Office of Compliance. The team leverages an interdisciplinary bench of attorneys, consultants, and scientists to provide you with insight and practical advice. We handle matters including:

  • Clinical trial contracting
  • Research compliance
  • Product development strategy and early agency interactions
  • Patient-focused drug development (including patient advocacy group collaborations)
  • Software as a medical device
  • Current good manufacturing practice (CGMP) and quality system regulations and expectations
  • Laboratory audits
  • Agency determinations (i.e., INDs, IDEs, and expanded access)
  • Risk evaluations and mitigation strategies (REMS)
  • Promotional communications and advertising
  • Privacy protection policies and enforcement
  • Post-marketing surveillance

We also support clients as they innovate using advanced manufacturing techniques and platform technologies, artificial intelligence (AI), machine learning (ML), and other software-based technologies.  

Food and Dietary Supplements

Leading food and dietary supplement companies confront critical legal, regulatory, and business challenges every day. We help you develop and execute strategies related to the science, economics, markets, government regulation, and public relations aspects of the farm to-table cycle. When disputes, regulatory changes, product recalls, or legal suits emerge, our regulatory and litigation teams provide peace of mind as you implement new compliance protocols or tackle high-stakes litigation.

Cosmetics

Makers of cosmetics and personal care products must continuously adapt and expand product offerings to reflect the growing desire of consumers to express their beauty and individuality. At the same time, oversight has never been greater, as we watch FDA implement federal legislation to modernize cosmetics regulation. Creative marketing and advertising of these products may fall outside legal parameters and result in enforcement action by regulatory agencies. States have become increasingly involved in cosmetic regulation as it relates to product ingredients and consumer health. We work with you to meet these emerging challenges head-on. We review product ingredients, help navigate registration requirements, and advise on prospective advertising and labeling claims that are the basis for legal challenges by regulators and competitors.

Animal Health

Companies making new animal drugs, medicated feeds, and feed additives, as well as pet food and animal feed, need in-depth knowledge to identify applicable regulations and implement efficient development, manufacturing, and marketing of animal food and drugs. We guide clients through interactions with the FDA and the US Department of Agriculture by delivering industry insight and practical advice on complex legal issues related to adverse event reporting, recalls, criminal investigations, and product liability.

Insights & Events

Latest

Speaking Engagement Recap March 18, 2026

AI-Enabled Medical Devices: Navigating New Liability Risks and Regulatory Frontiers

Defense Research Institute’s Drug and Medical Device Committee Meeting
1 min read
Updates March 2026

FDA Finalizes Rule Requiring 12-Digit National Drug Code (NDC)

Two Little Digits, One Very Big Operational Headache
4 min read
Updates February 2026

FDA Publishes Long-Awaited Draft Guidance on “Plausible Mechanism Framework” to Spur the Development of New Individualized Medicines

Anticipated Deadline for Comments Is April 27, 2026
7 min read
News February 2026

Jessica Natali Honored With Temple Law’s 2026 Women’s Law Caucus Leadership Award

1 min read
Published Articles February 2026

What to Know About Indiana’s New Data Protection Law

Indianapolis Business Journal
1 min read
Updates February 2026

US and International Developments in Artificial Intelligence

Artificial Intelligence Briefing
6 min read
Updates January 2026

Key Updates in FDA’s 2026 General Wellness and Clinical Decision Support Software Guidance

Greater Clarity, Transparency, and Alignment in Digital Health Regulation
9 min read
Updates December 2025

Significant Drug & Device Developments of 2025

Drug & Device Companies Need to Be Vigilant and Nimble in Adapting to These Shifts
17 min read
Speaking Engagement Recap November 07, 2025

Data, Dangers, & Developments in Drug Supply Chain Security & Safety

American Society for Pharmacy Law: 2025 Developments in Pharmacy Law
1 min read
Press Release May 2025

Faegre Drinker Grows Life Sciences Consulting Team With Nationally Recognized Patient Experience Researcher Holly Peay, PhD

2 min read
Insights
Updates March 2026

FDA Finalizes Rule Requiring 12-Digit National Drug Code (NDC)

Two Little Digits, One Very Big Operational Headache
4 min read
Updates February 2026

FDA Publishes Long-Awaited Draft Guidance on “Plausible Mechanism Framework” to Spur the Development of New Individualized Medicines

Anticipated Deadline for Comments Is April 27, 2026
7 min read
Published Articles February 2026

What to Know About Indiana’s New Data Protection Law

Indianapolis Business Journal
1 min read
Updates February 2026

US and International Developments in Artificial Intelligence

Artificial Intelligence Briefing
6 min read
Updates January 2026

Key Updates in FDA’s 2026 General Wellness and Clinical Decision Support Software Guidance

Greater Clarity, Transparency, and Alignment in Digital Health Regulation
9 min read
Updates December 2025

Significant Drug & Device Developments of 2025

Drug & Device Companies Need to Be Vigilant and Nimble in Adapting to These Shifts
17 min read
Published Articles November 2025

Navigating FDA Regulatory and Litigation Risks With Al-Enabled Medical Devices and Non-Device Software: A Landscape Analysis for Medical Product Counsel

Defense Research Institute’s For the Defense
1 min read
Updates November 2025

SCOTUS Weighs Trump Administration’s Tariff Authority Under IEEPA; Pharma and Device AI; and More

Biopharma & Medical Devices Briefing
7 min read
Updates October 2025

California’s Frontier Artificial Intelligence Act & More Developments

Artificial Intelligence Briefing
7 min read
Media Mentions October 2025

Libby Baney Comments on Uncertainty in Prescription Drug Market With the Washington Post

1 min read

Meet The Team

Meet The Full FDA-Regulated Products Team